Studies indicating the abortion drug mifepristone is unsafe have been retracted just before SCOTUS is scheduled to hear case that could ban medication abortion.
CSPI shares the belief of many scientists and researchers that the FDA's approval of aducanumab was not based on adequate scientific evidence of the drug’s effectiveness. In this comment, we encourage the Centers for Medicare and Medicaid Services not to approve aducamab outside of clinical trials.
CSPI president Dr. Peter G. Lurie testified on June 19, 2020, at a hearing of the House Science, Space, and Technology's Investigations and Oversight Subcommittee on the topic of repurposing therapeutic drugs for COVID-19.
The Food and Drug Administration typically treats the existence of new drug applications as confidential commercial information, not even acknowledging that they have been filed. But according to new research published in JAMA-Internal Medicine today, the filing of almost 90 percent of new drug applications (and similar applications for new biologic products) filed between 2010 and 2016 was disclosed by drug companies themselves in the form of press releases, filings with the Securities and Exchange Commission, or both—and typically within a week of the submission of the application to the FDA.